Pretraga

Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1252985

The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program

Pivot, X.; Poole, C.; Martín, M.; Gligorov, J.; Barrios, C.H.; Vrdoljak, Eduard; Zambetti, M.; Woodward, N.; Ten Tije, A.J.; Lindegger, N. et al.
The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program // EUROPEAN JOURNAL OF CANCER
Barcelona, Španjolska: Elsevier, 2018. str. S105-S106 doi:10.1016/s0959-8049(18)30542-2 (poster, međunarodna recenzija, sažetak, stručni)

CROSBI ID: 1252985 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program

Autori
Pivot, X. ; Poole, C. ; Martín, M. ; Gligorov, J. ; Barrios, C.H. ; Vrdoljak, Eduard ; Zambetti, M. ; Woodward, N. ; Ten Tije, A.J. ; Lindegger, N. ; Crespel, G. ; Truman, M. ; Steger, G.G.

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
EUROPEAN JOURNAL OF CANCER / - : Elsevier, 2018, S105-S106

Skup
11th European Breast Cancer Conference (EBCC)

Mjesto i datum
Barcelona, Španjolska, 21.03.2018. - 23.03.2018

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Phase IIIB umbrella study ; trastuzumab ; pertuzumab ; HER2-positive early breast cancer ; metastatic breast cancer (MBC) ; chemotherapy ; UmbHER1 program

Sažetak
Za ovaj rad nije dostupan sažetak.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA

Ustanove:
KBC Split,
Medicinski fakultet, Split

Profili:

Avatar Url Eduard Vrdoljak (autor)

Poveznice na cjeloviti tekst rada:

doi www.sciencedirect.com www.ejcancer.com

Citiraj ovu publikaciju:

Pivot, X.; Poole, C.; Martín, M.; Gligorov, J.; Barrios, C.H.; Vrdoljak, Eduard; Zambetti, M.; Woodward, N.; Ten Tije, A.J.; Lindegger, N. et al.
The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program // EUROPEAN JOURNAL OF CANCER
Barcelona, Španjolska: Elsevier, 2018. str. S105-S106 doi:10.1016/s0959-8049(18)30542-2 (poster, međunarodna recenzija, sažetak, stručni)
Pivot, X., Poole, C., Martín, M., Gligorov, J., Barrios, C., Vrdoljak, E., Zambetti, M., Woodward, N., Ten Tije, A. & Lindegger, N. (2018) The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program. U: EUROPEAN JOURNAL OF CANCER doi:10.1016/s0959-8049(18)30542-2.
@article{article, author = {Pivot, X. and Poole, C. and Mart\'{\i}n, M. and Gligorov, J. and Barrios, C.H. and Vrdoljak, Eduard and Zambetti, M. and Woodward, N. and Ten Tije, A.J. and Lindegger, N. and Crespel, G. and Truman, M. and Steger, G.G.}, year = {2018}, pages = {S105-S106}, DOI = {10.1016/s0959-8049(18)30542-2}, keywords = {Phase IIIB umbrella study, trastuzumab, pertuzumab, HER2-positive early breast cancer, metastatic breast cancer (MBC), chemotherapy, UmbHER1 program}, doi = {10.1016/s0959-8049(18)30542-2}, title = {The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program}, keyword = {Phase IIIB umbrella study, trastuzumab, pertuzumab, HER2-positive early breast cancer, metastatic breast cancer (MBC), chemotherapy, UmbHER1 program}, publisher = {Elsevier}, publisherplace = {Barcelona, \v{S}panjolska} }
@article{article, author = {Pivot, X. and Poole, C. and Mart\'{\i}n, M. and Gligorov, J. and Barrios, C.H. and Vrdoljak, Eduard and Zambetti, M. and Woodward, N. and Ten Tije, A.J. and Lindegger, N. and Crespel, G. and Truman, M. and Steger, G.G.}, year = {2018}, pages = {S105-S106}, DOI = {10.1016/s0959-8049(18)30542-2}, keywords = {Phase IIIB umbrella study, trastuzumab, pertuzumab, HER2-positive early breast cancer, metastatic breast cancer (MBC), chemotherapy, UmbHER1 program}, doi = {10.1016/s0959-8049(18)30542-2}, title = {The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program}, keyword = {Phase IIIB umbrella study, trastuzumab, pertuzumab, HER2-positive early breast cancer, metastatic breast cancer (MBC), chemotherapy, UmbHER1 program}, publisher = {Elsevier}, publisherplace = {Barcelona, \v{S}panjolska} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE

Citati:

    Altmetrijski pokazatelji:


    Podijeli:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font
    CROSBI koristi kolačiće (cookies) kako bi poboljšao funkcionalnost stranice.